Monday, November 23, 2009

Toxicologist position at the FDA

I was sent the following information by Dr. Dan Levy about a position currently being advertised by the FDA. If interested, please contact Dan at the contact information below.

The FDA Division of Dietary Supplement Programs (DDSP) is looking for a toxicologist/pharmacologist/interdisciplinary scientist to review pre-market safety notifications for new dietary ingredients (NDIs). NDIs include vitamins, minerals, amino acids, botanicals, dietary substances, or constituents, metabolites, etc of any of these. Safety reviews require evaluation of evidence of safety which frequently includes sub-chronic rodent toxicology studies and history of use in food and also sometimes clinical studies and published literature with various degrees of relevance. This information is reviewed within 75 days by a multi-disciplinary team which can include chemists, botanists, microbiologist and medical officers. The ideal candidate will demonstrate proficiency in an area of toxicology or pharmacology relevant to dietary supplements, ability to review animal toxicology data, ability to write clearly and concisely, and to work in a fast-paced interdisciplinary team environment. DDSP also initiates collaborative studies with extramural laboratory scientists to resolve scientific questions relevant to the safety of dietary supplements. Applications are accepted online only at USAjobs.gov (HHS-FDA-06-2010-0014 for “status” Federal employees, HHS-FDA-06-2010-0013 for all other U.S. Citizens). Hiring at the GS-14 level is possible with a demonstration of experience commensurate with a “nationally recognized expert” in a sub-discipline related to the position. Applicants are cautioned that the U.S. Office of Personnel Management definition of “toxicologist” may be more restrictive other definitions and that applying as a pharmacologist or biologist may be more appropriate to your qualifications. For information about the positions or the DDSP you are encouraged to contact Dan D. Levy at dan.levy@FDA.hhs.gov.

No comments: